Ultragenyx Q1 revenue $139M, reaffirms FY2025 guidance; UX111 PDUFA Aug 18, 2025

Ultragenyx Pharmaceutical Inc.

2025-Q1 EPS reported -$1.57 revenue$139,292,000

Q1 total revenue $139M (+28% YoY); net loss $151M ($1.57/share) vs $171M ($2.03) in Q1 2024.
Crysvita revenue $103M (+25% YoY); Dojolvi $17M; Evkeeza $11M; Mepsevii $8.4M.
Reaffirmed FY2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
UX111 BLA for Sanfilippo granted Priority Review; PDUFA date Aug 18, 2025; potential H2 launch.
DTX401 BLA for GSDIa expected mid-2025; GTX-102 Ph3 enrollment completion H2 2025; cash $563M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.